INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 177 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2020. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $263,377 | +3.5% | 5,057 | +25.8% | 0.00% | – |
| Q2 2023 | $254,408 | +32.0% | 4,020 | +13.0% | 0.00% | – |
| Q1 2023 | $192,786 | +16.1% | 3,559 | +14.3% | 0.00% | – |
| Q4 2022 | $166,000 | +7.8% | 3,114 | -5.9% | 0.00% | – |
| Q3 2022 | $154,000 | -84.1% | 3,308 | -80.5% | 0.00% | -100.0% |
| Q2 2022 | $966,000 | -35.8% | 16,932 | -31.1% | 0.00% | -33.3% |
| Q1 2022 | $1,504,000 | +1734.1% | 24,585 | +1467.9% | 0.00% | – |
| Q4 2021 | $82,000 | +127.8% | 1,568 | +63.3% | 0.00% | – |
| Q3 2021 | $36,000 | -20.0% | 960 | -13.2% | 0.00% | – |
| Q2 2021 | $45,000 | +87.5% | 1,106 | +55.6% | 0.00% | – |
| Q1 2021 | $24,000 | +4.3% | 711 | -3.4% | 0.00% | – |
| Q4 2020 | $23,000 | +4.5% | 736 | -13.7% | 0.00% | – |
| Q3 2020 | $22,000 | -63.3% | 853 | -63.9% | 0.00% | – |
| Q2 2020 | $60,000 | +81.8% | 2,363 | +9.9% | 0.00% | – |
| Q1 2020 | $33,000 | – | 2,150 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 359,000 | $18,790,000 | 7.62% |
| Velan Capital Investment Management LP | 150,000 | $7,851,000 | 6.09% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 195,000 | $10,206,000 | 4.14% |
| Vantage Consulting Group Inc | 226,670 | $11,864,000 | 3.19% |
| Vahanian & Associates Financial Planning Inc. | 71,742 | $3,755,000 | 3.03% |
| Nicholas Investment Partners, LP | 652,886 | $34,172,000 | 2.16% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $3,199,000 | 1.97% |
| Bellevue Group AG | 3,628,919 | $189,938,000 | 1.96% |
| WASATCH ADVISORS LP | 8,235,171 | $431,029,000 | 1.76% |
| Quantum Private Wealth, LLC | 77,622 | $4,062,000 | 1.54% |